Literature DB >> 23430103

Risk of fracture in patients with Parkinson's disease.

S Pouwels1, M T Bazelier, A de Boer, W E J Weber, C Neef, C Cooper, F de Vries.   

Abstract

UNLABELLED: The aim of the study was to determine fracture risk in incident Parkinson's disease (PD) patients. This study showed that fracture risk assessment may be indicated among patients with PD, in particular when they have recently used selective serotonin re-uptake inhibitors or high-dose antipsychotics, or have a history of fracture, falling, low body mass index (BMI) or renal disease.
INTRODUCTION: PD is a movement disorder associated with falling and detrimental effects on bone. Both are recognized risk factors for fracture. Therefore, the aim was to determine fracture risk in incident PD patients stratified by treatment, severity, duration of disease and related comorbidities.
METHODS: We conducted a retrospective cohort study using the UK General Practice Research Database (1987-2011). Each PD patient was matched by age, sex, calendar time and practice to a control patient without history of PD.
RESULTS: We identified 4,687 incident PD patients. Compared to controls, a statistically significant increased risk was observed for any fracture (adjusted hazard ratio [AHR], 1.89; 95 % confidence interval [CI], 1.67-2.14), osteoporotic fracture (AHR, 1.99; 95 % CI, 1.72-2.30) and hip fracture (AHR 3.08; 95 % CI, 2.43-3.89). Fracture risk further increased with history of fracture, falling, low BMI, renal disease, antidepressant use and use of high-dose antipsychotics.
CONCLUSION: This study showed that incident PD patients have a statistically significant increased risk of fracture. Therefore, fracture risk assessment may be indicated among PD patients, who, besides the general risk factors for fracture, like increasing age and female gender, have recently used selective serotonin re-uptake inhibitors or high-dose antipsychotics or have a history of fracture, falling, low BMI or renal disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23430103     DOI: 10.1007/s00198-013-2300-2

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  33 in total

1.  Risk factors for hip fracture among elderly patients with Parkinson's disease.

Authors:  Y Sato; M Kaji; T Tsuru; K Oizumi
Journal:  J Neurol Sci       Date:  2001-01-01       Impact factor: 3.181

2.  The UK General Practice Research Database.

Authors:  T Walley; A Mantgani
Journal:  Lancet       Date:  1997-10-11       Impact factor: 79.321

3.  The burden of osteoporotic fractures: a method for setting intervention thresholds.

Authors:  J A Kanis; A Oden; O Johnell; B Jonsson; C de Laet; A Dawson
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

4.  Social anxiety in patients with Parkinson's disease.

Authors:  Basak Bolluk; Erguvan Tugba Ozel-Kizil; Muhittin Cenk Akbostanci; Esref Cem Atbasoglu
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2010       Impact factor: 2.198

5.  Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture.

Authors:  P Vestergaard; L Rejnmark; L Mosekilde
Journal:  Osteoporos Int       Date:  2006-03-07       Impact factor: 4.507

6.  Long-acting {beta}2-agonists in adult asthma and the pattern of risk of death and severe asthma outcomes: a study using the GPRD.

Authors:  F de Vries; E Setakis; B Zhang; T P van Staa
Journal:  Eur Respir J       Date:  2010-03-29       Impact factor: 16.671

7.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

8.  A prospective study of alcoholism and the risk of Parkinson's disease.

Authors:  Miguel A Hernán; Giancarlo Logroscino; Luis A García Rodríguez
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

9.  A meta-analysis of six prospective studies of falling in Parkinson's disease.

Authors:  Ruth M Pickering; Yvette A M Grimbergen; Una Rigney; Ann Ashburn; Gordon Mazibrada; Brian Wood; Peggy Gray; Graham Kerr; Bastiaan R Bloem
Journal:  Mov Disord       Date:  2007-10-15       Impact factor: 10.338

10.  The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results.

Authors:  T P Van Staa; L Abenhaim; C Cooper; B Zhang; H G Leufkens
Journal:  Pharmacoepidemiol Drug Saf       Date:  2000-09       Impact factor: 2.890

View more
  18 in total

1.  Association Between Change in Body Mass Index, Unified Parkinson's Disease Rating Scale Scores, and Survival Among Persons With Parkinson Disease: Secondary Analysis of Longitudinal Data From NINDS Exploratory Trials in Parkinson Disease Long-term Study 1.

Authors:  Anne-Marie A Wills; Adriana Pérez; Jue Wang; Xiao Su; John Morgan; Suja S Rajan; Maureen A Leehey; Gregory M Pontone; Kelvin L Chou; Chizoba Umeh; Zoltan Mari; James Boyd
Journal:  JAMA Neurol       Date:  2016-03       Impact factor: 18.302

2.  Parkinson's disease and the risk of osteoporotic vertebral compression fracture: a nationwide population-based study.

Authors:  C K Lee; S K Choi; D A Shin; S Yi; K N Kim; I Kim; Y Ha
Journal:  Osteoporos Int       Date:  2018-02-19       Impact factor: 4.507

3.  Increased risk of all-cause mortality associated with domperidone use in Parkinson's patients: a population-based cohort study in the UK.

Authors:  Marina Simeonova; Frank de Vries; Sander Pouwels; Johanna H M Driessen; Hubert G M Leufkens; Suzanne M Cadarette; Andrea M Burden
Journal:  Br J Clin Pharmacol       Date:  2018-08-09       Impact factor: 4.335

4.  Risk and adverse outcomes of fractures in patients with Parkinson's disease: two nationwide studies.

Authors:  Y-F Huang; Y-G Cherng; S P C Hsu; C-C Yeh; Y-C Chou; C-H Wu; T-L Chen; C-C Liao
Journal:  Osteoporos Int       Date:  2015-02-12       Impact factor: 4.507

5.  Fracture risk and impact of osteoporosis in patients with Parkinson's disease: a nationwide database study.

Authors:  Tae-Lim Kim; Seong Jun Byun; Min Yong Seong; Byung-Mo Oh; Sang Jun Park; Han Gil Seo
Journal:  J Bone Miner Metab       Date:  2022-03-26       Impact factor: 2.626

6.  Fracture risk in Parkinson's disease according to its severity and duration.

Authors:  Hye Yeon Koo; Eun Bin Cho; Sung Hye Kong; Kyungdo Han; Kyu Na Lee; Jung Eun Yoo; Ju-Hong Min; Sohyun Chun; Dong Wook Shin
Journal:  Osteoporos Int       Date:  2022-10-07       Impact factor: 5.071

Review 7.  Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.

Authors:  S Binks; R Dobson
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

8.  Parkinson's disease and osteoporosis: basic and clinical implications.

Authors:  Carolina A Figueroa; Clifford J Rosen
Journal:  Expert Rev Endocrinol Metab       Date:  2020-04-26

9.  Use of Glucagon-Like-Peptide 1 Receptor Agonists and Risk of Fracture as Compared to Use of Other Anti-hyperglycemic Drugs.

Authors:  Johanna H M Driessen; Hein A W van Onzenoort; Jakob Starup-Linde; Ronald Henry; Andrea M Burden; Cees Neef; Joop P van den Bergh; Peter Vestergaard; Frank de Vries
Journal:  Calcif Tissue Int       Date:  2015-07-17       Impact factor: 4.333

10.  Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom.

Authors:  I E M Bultink; N C Harvey; A Lalmohamed; C Cooper; W F Lems; T P van Staa; F de Vries
Journal:  Osteoporos Int       Date:  2013-12-03       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.